MedTrace Logo

Depression and Anxiety in Rheumatoid Arthritis

NCT02122406 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2016-10-10

Study results available
· View outcomes & findings →

Summary

The primary endpoint of this study is to evaluate the prevalence of anxiety and depressive disorders, and their relationship with disease activity, in patients with rheumatoid arthritis treated with biological drugs

Conditions

Interventions

OTHER

Hospital Anxiety and Depression Scale (HADS) questionnaire

Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire

Sponsors & Collaborators

  • University of Pavia

    lead OTHER

Principal Investigators

  • Roberto Caporali, MD · University of Pavia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02122406 on ClinicalTrials.gov